Trial Information

Summary: A Randomized, Double Blind, Placebo Controlled Trial of Immunotherapy with Autologous Antigen-Loaded Dendritic Cells For Asymptomatic Metastatic Hormone Refractory Prostate Cancer.

You may qualify to participate in this Phase 3 clinical trial if you have all of the following:

  • Cancer that has spread outside the prostate (metastatic)
  • Cancer that has progressed while on hormone therapy
  • Gleason Score of 7 or lower
  • No cancer related pain

Contact:

Maureen Lampo, Study Coordinator
Staten Island Urological Research, P.C.
1800 Clove Road
Staten Island, NY 10304
Telephone: 718-720-6040
Fax: 718-720-6523
Email:

Profile Page: Staten Island Urological Research, P.C., Staten Island, NY

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 5:43:49 AM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA